Skip to main content

Advertisement

Fig. 2 | Clinical Epigenetics

Fig. 2

From: DNA-methylation in C1R is a prognostic biomarker for acute myeloid leukemia

Fig. 2

DNA-methylation in C1R is associated with clinical parameters. a The CpG site cg08799922 is positioned in a regulatory region in the C1R gene, with binding sites of the architectural protein CTCF and cohesin components SMC1 and RAD21 in close proximity [20]. b Beta-value range of 194 AML patients [9] (yellow) and 656 healthy individuals [19] (brown) at 11 CpGs that are associated with C1R. Particularly, our selected CpG cg08799922 (in 5’UTR; red) and another site cg06915053 (first upstream in TSS200) are associated with OS. c Overall, AML patients [9] with lower DNAm (<27 % DNAm level) at cg08799922 (C1R) have higher gene expression of C1R. Correlation of DNAm at cg08799922 (C1R) with bone marrow blasts (d), gender (e), cytogenetic risk (f), and AML FAB-subtype classification (g). *P < 0.01, **P < 0.001, and ***P < 0.0001 by Mann-Whitney test. h Enrichment of specific mutations according to DNAm level at C1R (P values: hypergeometric distribution)

Back to article page